Day: December 4, 2025

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profile The interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be presented in a poster session at ESMO-IO on December 10, 2025ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that new data from the expanded...

Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) — Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at an initial public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and estimated offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any. The Ordinary Shares are expected to begin trading...

SINGAPORE, Dec. 03, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Jason Leow as a Senior Managing Director within the firm’s Strategic Communications segment. Mr. Leow, who is based in Singapore, brings more than 25 years of experience in financial communications, C-suite advisory and stakeholder engagement across Asia, Europe and the United States. In his role at FTI Consulting, he will work closely with the Asia Leadership Team and the firm’s global Senior Managing Director group to drive growth across Southeast Asia and strengthen alignment within the firm’s international Strategic Communications network. His appointment underscores the firm’s commitment to expanding its strategic communications capabilities in the region, particularly in areas such as M&A, ESG, shareholder...

VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1)(“Monument” or the “Company”) is pleased to announce the first 16 drill hole results from its first BR/Felda mine expansion drilling program and update mine expansion drilling activities at the Selinsing Gold Mine including Selinsing and Buffalo Reef gold projects, located in Pahang State on the Central Gold Belt of Western Malaysia. Ms. Cathy Zhai, President and CEO of Monument Mining commented: “We are encouraged by the first 16 drill hole assay results from the exploration drill program within targeted potential mine expansion areas, including both outside of Buffalo Reef/Felda pit shells (“BR/Felda mine expansion drilling”) and Selinsing pit shells (“Selinsing mine expansion drilling”)...